HyperLight Corporation, creator of the TFLN Chiplet(TM) platform, today announced the release of its 145 GHz Packaged Intensity Modulator (IM), expanding the company's high-speed modulator portfolio.
Of the 300 patients in the PARCER trial, 93 faced grades ≥2 adverse events (3D-CRT = 59, IG-IMRT = 34). Patients in the 3D-CRT and IG-IMRT arms spent an average of 2.39 years and 1.96 years in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results